- Home
- CNSP vs GRI Comparison
CNSP vs GRI Comparison
Compare CNSP & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- GRI
- Stock Information
- Founded
- CNSP 2017
- GRI 2018
- Country
- CNSP United States
- GRI United States
- Employees
- CNSP N/A
- GRI N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- CNSP Health Care
- GRI Health Care
- Exchange
- CNSP Nasdaq
- GRI Nasdaq
- Market Cap
- CNSP 4.0M
- GRI 4.3M
- IPO Year
- CNSP 2019
- GRI N/A
- Fundamental
- Price
- CNSP $7.20
- GRI $1.97
- Analyst Decision
- CNSP Strong Buy
- GRI Strong Buy
- Analyst Count
- CNSP 1
- GRI 2
- Target Price
- CNSP $20.00
- GRI $22.50
- AVG Volume (30 Days)
- CNSP 13.8K
- GRI 174.1K
- Earning Date
- CNSP 11-17-2025
- GRI 11-14-2025
- Dividend Yield
- CNSP N/A
- GRI N/A
- EPS Growth
- CNSP N/A
- GRI N/A
- EPS
- CNSP N/A
- GRI N/A
- Revenue
- CNSP N/A
- GRI N/A
- Revenue This Year
- CNSP N/A
- GRI N/A
- Revenue Next Year
- CNSP N/A
- GRI N/A
- P/E Ratio
- CNSP N/A
- GRI N/A
- Revenue Growth
- CNSP N/A
- GRI N/A
- 52 Week Low
- CNSP $4.93
- GRI $1.10
- 52 Week High
- CNSP $114.00
- GRI $16.92
- Technical
- Relative Strength Index (RSI)
- CNSP 46.98
- GRI 54.70
- Support Level
- CNSP $6.30
- GRI $1.58
- Resistance Level
- CNSP $7.07
- GRI $2.29
- Average True Range (ATR)
- CNSP 0.59
- GRI 0.19
- MACD
- CNSP 0.06
- GRI 0.04
- Stochastic Oscillator
- CNSP 34.80
- GRI 57.53
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.